Loading resource…

American College of Cardiology Foundation
The document provides an overview of the risks associated with anthracycline chemotherapy, particularly in patients with pre-existing cardiovascular conditions. It emphasizes the importance of risk assessment tools and guidelines from the European Society of Cardiology for managing patients undergoing treatment with anthracyclines. The recommendations include strategies for cardioprotection to minimize the risk of cardiotoxicity, which remains a significant concern in oncology.
No account needed